Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
CBPO's Cash to Debt is ranked higher than
83% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. CBPO: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CBPO' s Cash to Debt Range Over the Past 10 Years
Min: 0.65  Med: 6.61 Max: No Debt
Current: No Debt
Equity to Asset 0.70
CBPO's Equity to Asset is ranked higher than
52% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CBPO: 0.70 )
Ranked among companies with meaningful Equity to Asset only.
CBPO' s Equity to Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.54 Max: 0.7
Current: 0.7
0.29
0.7
Interest Coverage 48.05
CBPO's Interest Coverage is ranked lower than
82% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBPO: 48.05 )
Ranked among companies with meaningful Interest Coverage only.
CBPO' s Interest Coverage Range Over the Past 10 Years
Min: 6.9  Med: 35.62 Max: 93.8
Current: 48.05
6.9
93.8
F-Score: 7
Z-Score: 15.65
M-Score: -2.20
WACC vs ROIC
18.90%
45.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 45.32
CBPO's Operating margin (%) is ranked higher than
94% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. CBPO: 45.32 )
Ranked among companies with meaningful Operating margin (%) only.
CBPO' s Operating margin (%) Range Over the Past 10 Years
Min: 21.04  Med: 43.13 Max: 51.58
Current: 45.32
21.04
51.58
Net-margin (%) 29.92
CBPO's Net-margin (%) is ranked higher than
91% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. CBPO: 29.92 )
Ranked among companies with meaningful Net-margin (%) only.
CBPO' s Net-margin (%) Range Over the Past 10 Years
Min: 1.86  Med: 24.86 Max: 29.15
Current: 29.92
1.86
29.15
ROE (%) 31.22
CBPO's ROE (%) is ranked higher than
96% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. CBPO: 31.22 )
Ranked among companies with meaningful ROE (%) only.
CBPO' s ROE (%) Range Over the Past 10 Years
Min: 5.04  Med: 27.33 Max: 42.37
Current: 31.22
5.04
42.37
ROA (%) 18.18
CBPO's ROA (%) is ranked higher than
96% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. CBPO: 18.18 )
Ranked among companies with meaningful ROA (%) only.
CBPO' s ROA (%) Range Over the Past 10 Years
Min: 1.84  Med: 16.03 Max: 23.86
Current: 18.18
1.84
23.86
ROC (Joel Greenblatt) (%) 57.20
CBPO's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. CBPO: 57.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CBPO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 72.32  Med: 89.14 Max: 211.2
Current: 57.2
72.32
211.2
Revenue Growth (3Y)(%) 18.20
CBPO's Revenue Growth (3Y)(%) is ranked higher than
77% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. CBPO: 18.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CBPO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 8.3  Med: 18.20 Max: 57.5
Current: 18.2
8.3
57.5
EBITDA Growth (3Y)(%) 36.60
CBPO's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. CBPO: 36.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CBPO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.5  Med: 27.00 Max: 72.3
Current: 36.6
5.5
72.3
EPS Growth (3Y)(%) 59.40
CBPO's EPS Growth (3Y)(%) is ranked higher than
94% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CBPO: 59.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CBPO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 7  Med: 52.20 Max: 155.5
Current: 59.4
7
155.5
» CBPO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

CBPO Guru Trades in Q4 2014

Pioneer Investments 5,525 sh (New)
Jim Simons 276,100 sh (+24.03%)
Chuck Royce 2,900 sh (unchged)
» More
Q1 2015

CBPO Guru Trades in Q1 2015

Jim Simons 348,722 sh (+26.30%)
Chuck Royce Sold Out
Pioneer Investments Sold Out
» More
Q2 2015

CBPO Guru Trades in Q2 2015

Steven Cohen 53,400 sh (New)
Jim Simons 319,500 sh (-8.38%)
» More
Q3 2015

CBPO Guru Trades in Q3 2015

Jim Simons 389,100 sh (+21.78%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CBPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 33.42
CBPO's P/E(ttm) is ranked lower than
52% of the 374 Companies
in the Global Biotechnology industry.

( Industry Median: 35.73 vs. CBPO: 33.42 )
Ranked among companies with meaningful P/E(ttm) only.
CBPO' s P/E(ttm) Range Over the Past 10 Years
Min: 2.92  Med: 17.29 Max: 124.23
Current: 33.42
2.92
124.23
Forward P/E 23.42
CBPO's Forward P/E is ranked lower than
70% of the 347 Companies
in the Global Biotechnology industry.

( Industry Median: 16.47 vs. CBPO: 23.42 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 33.42
CBPO's PE(NRI) is ranked lower than
54% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 33.50 vs. CBPO: 33.42 )
Ranked among companies with meaningful PE(NRI) only.
CBPO' s PE(NRI) Range Over the Past 10 Years
Min: 2.92  Med: 14.85 Max: 129.2
Current: 33.42
2.92
129.2
P/B 7.75
CBPO's P/B is ranked lower than
93% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.49 vs. CBPO: 7.75 )
Ranked among companies with meaningful P/B only.
CBPO' s P/B Range Over the Past 10 Years
Min: 0.84  Med: 3.16 Max: 11.71
Current: 7.75
0.84
11.71
P/S 9.88
CBPO's P/S is ranked lower than
52% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. CBPO: 9.88 )
Ranked among companies with meaningful P/S only.
CBPO' s P/S Range Over the Past 10 Years
Min: 0.68  Med: 2.25 Max: 13.14
Current: 9.88
0.68
13.14
PFCF 43.07
CBPO's PFCF is ranked lower than
63% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 27.59 vs. CBPO: 43.07 )
Ranked among companies with meaningful PFCF only.
CBPO' s PFCF Range Over the Past 10 Years
Min: 1.92  Med: 10.47 Max: 57.21
Current: 43.07
1.92
57.21
POCF 28.01
CBPO's POCF is ranked higher than
51% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 25.75 vs. CBPO: 28.01 )
Ranked among companies with meaningful POCF only.
CBPO' s POCF Range Over the Past 10 Years
Min: 1.62  Med: 7.20 Max: 37.2
Current: 28.01
1.62
37.2
EV-to-EBIT 19.70
CBPO's EV-to-EBIT is ranked higher than
52% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 20.26 vs. CBPO: 19.70 )
Ranked among companies with meaningful EV-to-EBIT only.
CBPO' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.2  Med: 5.80 Max: 26.9
Current: 19.7
1.2
26.9
EV-to-EBITDA 18.54
CBPO's EV-to-EBITDA is ranked lower than
53% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 17.11 vs. CBPO: 18.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBPO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.1  Med: 5.20 Max: 25.3
Current: 18.54
1.1
25.3
PEG 1.84
CBPO's PEG is ranked higher than
61% of the 90 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. CBPO: 1.84 )
Ranked among companies with meaningful PEG only.
CBPO' s PEG Range Over the Past 10 Years
Min: 0.42  Med: 1.20 Max: 2.13
Current: 1.84
0.42
2.13
Current Ratio 5.49
CBPO's Current Ratio is ranked higher than
56% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. CBPO: 5.49 )
Ranked among companies with meaningful Current Ratio only.
CBPO' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 2.50 Max: 5.78
Current: 5.49
1.03
5.78
Quick Ratio 3.63
CBPO's Quick Ratio is ranked lower than
54% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CBPO: 3.63 )
Ranked among companies with meaningful Quick Ratio only.
CBPO' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.50 Max: 3.92
Current: 3.63
0.54
3.92
Days Inventory 400.35
CBPO's Days Inventory is ranked lower than
92% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. CBPO: 400.35 )
Ranked among companies with meaningful Days Inventory only.
CBPO' s Days Inventory Range Over the Past 10 Years
Min: 280.18  Med: 433.17 Max: 490.33
Current: 400.35
280.18
490.33
Days Sales Outstanding 43.90
CBPO's Days Sales Outstanding is ranked higher than
69% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. CBPO: 43.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBPO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.44  Med: 24.03 Max: 39.95
Current: 43.9
2.44
39.95
Days Payable 19.25
CBPO's Days Payable is ranked lower than
79% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. CBPO: 19.25 )
Ranked among companies with meaningful Days Payable only.
CBPO' s Days Payable Range Over the Past 10 Years
Min: 18.05  Med: 40.80 Max: 98.28
Current: 19.25
18.05
98.28

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 13.95
CBPO's Price/Net Current Asset Value is ranked lower than
76% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 5.14 vs. CBPO: 13.95 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CBPO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.4  Med: 8.59 Max: 695
Current: 13.95
2.4
695
Price/Tangible Book 8.03
CBPO's Price/Tangible Book is ranked lower than
70% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 3.93 vs. CBPO: 8.03 )
Ranked among companies with meaningful Price/Tangible Book only.
CBPO' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.16  Med: 3.73 Max: 24.65
Current: 8.03
1.16
24.65
Price/Projected FCF 3.19
CBPO's Price/Projected FCF is ranked lower than
51% of the 296 Companies
in the Global Biotechnology industry.

( Industry Median: 3.14 vs. CBPO: 3.19 )
Ranked among companies with meaningful Price/Projected FCF only.
CBPO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.99  Med: 1.75 Max: 3.67
Current: 3.19
0.99
3.67
Price/Median PS Value 4.38
CBPO's Price/Median PS Value is ranked lower than
78% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: 0.89 vs. CBPO: 4.38 )
Ranked among companies with meaningful Price/Median PS Value only.
CBPO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 0.98 Max: 4.84
Current: 4.38
0.39
4.84
Price/Peter Lynch Fair Value 1.60
CBPO's Price/Peter Lynch Fair Value is ranked higher than
55% of the 111 Companies
in the Global Biotechnology industry.

( Industry Median: 1.67 vs. CBPO: 1.60 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CBPO' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.51  Med: 1.16 Max: 1.85
Current: 1.6
0.51
1.85
Price/Graham Number 3.45
CBPO's Price/Graham Number is ranked lower than
65% of the 442 Companies
in the Global Biotechnology industry.

( Industry Median: 2.43 vs. CBPO: 3.45 )
Ranked among companies with meaningful Price/Graham Number only.
CBPO' s Price/Graham Number Range Over the Past 10 Years
Min: 0.43  Med: 1.56 Max: 11.5
Current: 3.45
0.43
11.5
Earnings Yield (Greenblatt) (%) 5.05
CBPO's Earnings Yield (Greenblatt) (%) is ranked higher than
85% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. CBPO: 5.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CBPO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.7  Med: 17.30 Max: 82.6
Current: 5.05
3.7
82.6
Forward Rate of Return (Yacktman) (%) 22.38
CBPO's Forward Rate of Return (Yacktman) (%) is ranked higher than
68% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. CBPO: 22.38 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CBPO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 19.4  Med: 21.75 Max: 35.3
Current: 22.38
19.4
35.3

More Statistics

Revenue(Mil) $286
EPS $ 3.21
Beta2.31
Short Percentage of Float5.65%
52-Week Range $67.50 - 144.29
Shares Outstanding(Mil)26.53

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0CB.Germany, CBPO.Mexico,
China Biologic Products Inc was originally incorporated on December 20, 1989 under the laws of the State of Texas as Shepherd Food Equipment, Inc. On November 20, 2000, Shepherd Food Equipment, Inc. changed its corporate name to Shepherd Food Equipment, Inc. Acquisition Corp., which is the survivor of a merger with GRC Holdings, Inc. on May 28, 2003. On January 10, 2007, the Company was converted into a Delaware corporation and changed its name to China Biologic Products, Inc. It is a biopharmaceutical company which is engaged in the research, development, manufacturing and sales of human plasma-based pharmaceutical products in China. The Company has two majority subsidiaries, Shandong Taibang, a company based in Tai'an, Shandong Province and Guizhou Taibang, a company based in Guiyang, Guizhou Province. The Company's products are human albumin and immunoglobulin products. Albumin has been used for almost 50 years to treat critically ill patients by replacing lost fluid and maintaining adequate blood volume and pressure. Immunoglobulin is used for certain disease prevention and treatment by enhancing specific immunity. These products use human plasma as the principal raw material. Human albumin and human immunoglobulin for intravenous injection, or IVIG products, are the top-selling products. The Company sells its products to hospitals and inoculation centers in the PRC directly or through approved distributors.
» More Articles for CBPO

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: ULTA, MIND, DG, PSA, CBPO, CNK Dec 20 2011 
Weekly CEO Sells Highlight: CTSH, CBPO, TCB, SRCL Sep 12 2010 

More From Other Websites
Caixin China Services and Composite PMI Improved in January Feb 05 2016
New Strong Sell Stocks for February 5th Feb 05 2016
Spread Reducing between Onshore and Offshore Yuan Jan 27 2016
China Biologic Products, Inc. – Value Analysis (NASDAQ:CBPO) : January 26, 2016 Jan 26 2016
China Biologic Products, Inc. breached its 50 day moving average in a Bullish Manner : January 26,... Jan 26 2016
China Biologic Products, Inc. breached its 50 day moving average in a Bearish Manner : January 14,... Jan 14 2016
China Biologic Products: CBPO Falls 5.4% in Session Jan 07 2016
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 04 2016
China Biologic to Attend the 34th Annual J.P. Morgan Healthcare Conference Jan 04 2016
The Zacks Analyst Blog Highlights: Alibaba, China Biologic Products, Weibo, JinkoSolar Holding and... Dec 24 2015
Can the Rally in China Biologic Products (CBPO) Shares Continue? Dec 24 2015
Forget Alibaba, Bet on These 5 Winning China Stocks of 2015 Dec 23 2015
CHINA BIOLOGIC PRODUCTS, INC. Financials Dec 08 2015
Is Heartland Payment Systems, Inc. (HPY) Going to Burn These Hedge Funds? Dec 04 2015
Is China Biologic Products Inc (CBPO) A Good Stock To Buy? Nov 23 2015
China Biologic Products, Inc. Earnings Q3, 2015 Nov 18 2015
Edited Transcript of CBPO earnings conference call or presentation 4-Nov-15 12:30pm GMT Nov 04 2015
China Biologic Products posts 3Q profit Nov 03 2015
China Biologic Products posts 3Q profit Nov 03 2015
China Biologic Reports Financial Results for the Third Quarter of 2015 Nov 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK